

Heron Evidence Development

Publications List

as at November 2008

2008

Lee CW, Buckley F, Costello S, Kelly S. (2008) A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma. *Current Medical Research & Opinion* 24(8) 2265-70

Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, et al. (2008) Cost-effectiveness analysis of natalizumab compared with other disease modifying treatments for people with highly active relapsing-remitting multiple sclerosis in the UK. *Pharmacoeconomics* 26(7) 617-27

Howard P, Knight C, Boler A, Baker C. (2008) Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model – application to a population of US adult smokers. *Pharmacoeconomics* 26(6) 497-511

Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D, Kopp Z. (2008) The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. *European Urology* 54(3) 543-62

Denton CP, Nihtyanova S, Hunsche E, Gani R. (2008) Economic implications of severe digital ulcer disease – a cost of illness analysis of patients receiving specialized care in the UK. *Annals of the Rheumatic Diseases* 67(Suppl II) 431

Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. (2008) The safety and tolerability of antimuscarinic treatments in overactive bladder: results from an update of a systematic review and meta-analysis. Presentation 69 – 33rd annual meeting of the International Urogynecological Association

Khullar V, Chapple C, Gabriel Z, Muston D, Bitoun CE, Weinstein D. (2008) The patient-perceived effects of antimuscarinic treatment: results from an update of a systematic review and meta-analysis. Presentation 70 – 33rd annual meeting of the International Urogynecological Association

Narvilkar P, Mahajan A, Dimri S, Kumar R, Seghal M. (2008) Role of disease specific instruments in the measurement of Health-Related Quality of Life in cancer clinical trials. Podium presentation QL6 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Cann K, Karia R, Plested M, Samuels E. (2008) A comparison of reasons for recommendation and rejection in four health technology appraisal systems: NICE, SMC, CADTH and PBAC. Podium presentation HT3 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Karia R, Plested M, Cann K, Zwaferink H. (2008) Update of results and outcomes of NICE single technology appraisals – economic criticisms, Podium presentation HT2 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Lee CW, Stoddart SD, Muston D, Buckley F, Costello S, Kelly S. (2008) Systematic review and meta-analysis of RCTs regarding the comparative incidence of hyperaemia of prostaglandin topical glaucoma medications. Poster presentation PSS24 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Lock K, Samuels E. (2008) Trends in research into central nervous system disorders: the influence of an aging population. Poster presentation PND28 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Samuels E, Stoddart SD, Lock K, Karia R. (2008) Huntington's disease: where have we been? Poster presentation PND2 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Muston D, Alnwick K. (2008) Systematic review reliability: sensitivity and specificity of one vs. two reviews. Poster presentation PMC63 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Proudfoot CW, Alnwick K. (2008) What proportion of diseases are QALYS an irrelevant measure for? Poster presentation PMC45 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Ubhadiya BS, Gautum C, Narvilkar P, Singh N, Bhanderi M, Dimri S. (2008) Design and reporting trends in piggy-back economic trials. Poster presentation PMC8 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Proudfoot CW, Stoddart SD, Muston D. (2008) Has the quality of randomized controlled trials increased with time: an analysis of data from 5 systematic reviews. Poster presentation PMC2 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Arora M, Srivastava K, Siddiqui MK, Verma J, Ahuja M, Sharma S. (2008) Socio-economic impact of avian influenza in South-East Asia and neighbouring high risk countries. Poster presentation PIN36 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Chawla A, Kumar R, Aneja G, Bhanderi M, Sehgal M. (2008) Pharmacogenomics: relevance and applicability in post-genomic era (HIV-therapy). Poster presentation PIN7 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008.

Jackson D, Proudfoot CW, Knight CJ, Cann K, Lock K. (2008) Inappropriate sedation in ICUs: evidence from the literature. Poster presentation PHP57 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Jackson D, Proudfoot CW, Knight CJ, Cann K, Lock K. (2008) Impact of ICU sedation practice on patient morbidity, cost and hospital resource use: a systematic review. Poster presentation PHP56 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Samuels E, Plested M. (2008) Categorising research: where is the focus? Poster presentation PHP46 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Nixon F. (2008) The reimbursement of orphan drugs across Europe. Poster presentation PHP45 - 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Bhanderi M, Singh N, Kumar R, Chawla A, Sehgal M. (2008) Quality of life measurement in current clinical trials: focus on chronic diseases. Poster presentation PMC5 - 3rd annual Asia-Pacific meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Karia R, Gani R, Perard R and Cann K. (2008) A comparison of three technology appraisal systems: NICE, SMC and CADTH. Podium presentation HP1 – 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Gani R, Samuels ER, Hughes S, Giovanonni G. (2008) A cost effectiveness analysis of natalizumab vs. interferon-beta and glatiramer acetate in patients with active relapsing-remitting multiple sclerosis currently failing on existing therapy. Poster presentation PND13 - 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Lee CW, Buckley F, Costello S, Stoddart SD, Kelly S. (2008) The RCT evidence of comparative effectiveness and safety of topical glaucoma medication. Poster presentation PSS4 - 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Muston D, Perard R, Nixon F. (2008) Characteristics of risk-sharing schemes in Europe. Poster presentation PHP68 - 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Proudfoot C, Plested M, Buckley F. (2008) Search strategies and results of systematic reviews. Poster presentation PMC1 - 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Muston D. (2008) Cost-effectiveness sensitivity to cost-effectiveness correlation: a simulation study. Poster presentation PMC21 - 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

Samuels E, Lock K, Karia R, Stoddart SD. (2008) Prevalence of research focuses on genetically-linked disorders: where have we been and where are we going? Poster presentation PMC53 - 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008

2007

Gani R, Nixon R, Hughes S, Jackson C. (2007) Estimating the rates of disability progression in people with relapsing-remitting multiple sclerosis. *Journal of medical economics*. 10, 79-89.

Buckley F, Proudfoot C, Boler A. (2007) Evaluating the effectiveness of search strategies for systematic review. *Value In Health* 10(6) A459

Gani R, Ravndal F. (2007) Assessing levels of association between health-care expenditure and health-care indicators in economically developed countries. *Value In Health* 10(3) A30

Karia R, Gani R, Boler A. (2007) Results and outcomes of NICE single technology appraisal process. *Value in Health* 10(6) A370-A371

Knight C, Howard P, Baker C. (2007) An evaluation of the cost-effectiveness of an extended course of varenicline in preventing smokers who have quit from relapsing. *Value in Health* 10(6) A472

Muston D. (2007) Examining incentives for subgrouping in NICE submissions. *Value in Health* 10(6) A371

Knight C, Howard P, Baker C. (2007) Estimating the incidence and prevalence of smoking

related morbidities using proxy values. *Value In Health* 10(3) A101

Muston D, Howard P. (2007) Price vs. access: a probabilistic model for guiding pricing decisions. *Value In Health* 10(3) A187

Orme M, Kerrigan J, Tyas D, Russel N, Nixon R. (2007) The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. *Value In Health*. 10(1): 54-60

Perard R, Gani R. European pricing and reimbursement update: optimal monetary benefits can depend on which country the process is initiated. *Value in Health* 10(6) A370

Tyas N, Kerrigan J, Russel N, Nixon R. (2007) The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? *Value In Health*. 10(5): 386-389

Hughes D, Sridhar F, Elliot R, Cowell W, Budhia S. Interventions that enhance medication compliance and persistence: theoretical grounding, and economic assessment. ISPOR 10th annual European congress, 20-13 October 2007, Dublin, Ireland

Muston D, Boler A. A practical guide to indirect/mixed treatment comparisons. ISPOR, 12th annual meeting, 19-23 May, Arlington, VA, USA

2006

Khullar V, Chapple C, Gabriel Z, Dooley JA. (2006) The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. *Urology*. 68(2 Suppl): 38-48.

Knight C. (2006) A care map for CHF in the UK. *Value In Health* 9(6), A355

Gani R, Hughes S, Jackson C, Nixon R. Disability progression rates in people with active relapsing-remitting multiple sclerosis. ECTRIMS 2006, 22nd congress of the European committee for treatment and research in multiple sclerosis, September 27-30 2006, Madrid, Spain

Howard P, Muston D. (2006) Bowel cancer screening. Balancing cost-effectiveness and affordability. *Value In Health* 9(6), A291

Muston D, Howard P, Lee D. (2006) A model for projecting bowel cancer incidence and mortality: application to the UK bowel cancer screening program. *Value In Health* 9(6), A290

Orme M, Boler A. (2006) Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence. *Pharmacoeconomics*. 24(8): 743-750

2005

Boler A, Lister S. (2005) Body mass index (BMI) and trends in GP consultations and prescribing: A UK NHS perspective. *Value In Health* 8(3), 255

Chapple C, Khullar V, Gabriel Z, Dooley J. (2005) The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta analysis. *European Urology*. 48, 5-26.

Chapple C, Khullar V, Gabriel Z, Dooley J. Comparative safety and tolerability of antimuscarinic treatments for overactive bladder. XXth EAU congress, 16-19 March 2005, Istanbul, Turkey

Gabriel Z, Khullar V, Chapple C, Dooley J. 'Lumping' versus 'Splitting': a comparison of two systematic reviews of antimuscarinic treatment for overactive bladder. 30th Meeting of the International Urogynecological Association, 9-12 August 2005, Copenhagen, Denmark

Khullar V, Chapple C, Gabriel Z, Dooley J. Duloxetine compared with antimuscarinics for the treatment of mixed urinary incontinence: an assessment of adverse events and withdrawals. 30th meeting of the International Urogynecological Association, 9-12 August 2005, Copenhagen, Denmark

Khullar V, Chapple C, Gabriel Z, Dooley J. Quality of life measurement in trials of antimuscarinic therapies for overactive bladder. XXth EAU Congress, 16-19 March 2005, Istanbul, Turkey

Richard L, Lister S. (2005) A preliminary analysis of the relationship between consultation length and prescriber activity in UK general practice. *Value In Health* 8(3), 295

Richard L, Lister S. (2005) An exploration of patient factors in influencing prescriber activity in UK general practice. *Value In Health* 8(3), 295

Richard L, Odeyemi I, Ward A. (2005) A review of the economic evidence for botulinum toxins in spasticity associated with stroke and cerebral palsy. *Value In Health* 8(6), A131

Richard L, Odeyemi I, Ward A. The need for consensus in outcome measures for assessment of interventions for spasticity. European Neurological Society, 15th Meeting, 18-22nd June 2005, Vienna, Austria

2004

Boler A, Howard P. (2004) A systematic review of the effectiveness of total and partial laparoscopic fundoplication for the treatment of GORD. *Value In Health* 7(3), 346-347.

Gabriel Z, Richard L. (2004) Blood donation in the 21st century: motivation amidst crisis. *Value In Health* 7(3), 316-317

Gosden T, Costello S, Orme M, Howard P, Dooley J. (2004) Cost effectiveness of latanoprost in first line treatment of primary open angle glaucoma in the UK. *Value In Health* 7(6), 747

Howard P, Knight C. (2004) A clinical and cost effectiveness comparison of venlafaxine and selective serotonin reuptake inhibitors (SSRIS) in the management of patients with major depressive disorder from the perspective of an Austrian sickness fund. *Journal of medical economics*. 7, 93-106

Lenox-Smith A, Conway P, Knight C. (2004) Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. *Pharmacoeconomics*. 22(5): 311-319

Orme M, Howard P. (2004) The cost-effectiveness of methyl aminolevulinate photodynamic therapy (MAL-PDT) for difficult to treat actinic keratoses. *Value In Health* 7(3), 260-261

Orme M, Howard P. (2004) The cost-effectiveness of methyl aminolevulinic photodynamic therapy (MAL-PDT) for basal cell carcinoma. *Value In Health* 7(3), 248-249

Orme M, Daniels S. (2004) Calculating the cost of wound care in a community setting in the UK: an example using modern wound management dressings. *Value In Health* 7(6), 762

2003

Boler A, Wenk-Lang A, Howard P. (2003) A cost consequence analysis of new endoscopic, injectable treatment and existing interventions in gastro-oesophageal reflux disease. *Value In Health* 6(6), 613

Boler A, Howard P. (2003) The implications of combining heterogeneous patient populations in meta-analyses. *Value In Health* 6(6), 610-611

Bosanquet N, Domenighetti G, Beresniak A, Auray J, Crivelli L, et al. (2003) Equity, access and economic evaluation in rare diseases. *Pharm Dev Regul.* 1(3): 151-157

Conway P, Knight C. (2003) First and second year UK treatment costs associated with the use of anti-TNF drugs in patients with rheumatoid arthritis. *Rheumatology* 46(Suppl 1), 87

Orme ME, Jurewicz WA, Kumar N, McKechnie TL. (2003) The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes. *Pharmacoeconomics.* 21(17): 1263-1276

Richard L. (2003) A review of the pharmacotherapeutic management of pulmonary arterial hypertension. *Value In Health* 6(3), 6

Richard L. (2003) Pharmacoepidemiology: a review of its emerging role in outcomes research. *Value In Health* 6(3), 295

Wenk-Lang A, Knight C. (2003) Cost-effectiveness analyses of TAXUS(TM) drug-eluting stent in the UK. *Value In Health* 6(6), 661

2002

Boler A. (2002) Trends in data sources used for economic evaluation. *Value In Health* 5(6), 531-532.

Duru G, Auray JP, Beresniak A, Lamure M, Paine A, et al. (2002) Limitations of the methods used for calculating quality-adjusted life-year values. *Pharmacoeconomics.* 20(7): 463-473.

Ready A, Yi-Hua C, Barratt R, Sen S, Knight C, et al. (2002) Funding decisions for anti-rejection therapies; the use of real costs and economic models to predict cost-effectiveness. *British Transplantation Society*

Richard L, Howard P, Thorpe T. (2002) A review of the pharmacotherapeutic management of pulmonary arterial hypertension. *Value In Health* 5(6), 492-493.

Richard L. (2002) The relationship between disease area and type of economic study - does it exist. *Value In Health* 5(3), 212

2001

Daniels S, Kerrigan J. (2001) Modern wound dressings are more cost-effective than traditional gauze dressings in managing difficult to heal surgical wounds. European wound management association 2001, Dublin, Ireland.

Kerrigan J, Knight C. (2001) Do health care purchasers prefer paying for life extension of quality of life improvement? *Value In Health* 4(6), 423-424.

Ready A, Yi-Hua C, Barratt R, Sen S, Knight C (2001) Funding restrictions for new anti-rejection therapies in the UK. Modelling for cost-effectiveness may provide a means of challenge. Renal Association autumn meeting, 20-21 September 2001, The Royal College of Physicians, London, UK

2000

Hakim Z, Howard P, Farina C. (2000) Estimating health state preferences in obesity. *ISOQOL* 2000

Knight C, Ratcliffe A, Howard P, Farina C. (2000) Modelling of anti-obesity treatment: cost-effectiveness model in the UK. *Value In Health* 3(5), 361

1999

Sweetenham J, Hieke K, Kerrigan M, Howard P, Smarrt P (1999) Cost minimisation analysis of CHOP, fludarabine and rituximab for the treatment of relapsed, indolent B-cell non hodgkin's lymphoma in the UK. *British Journal of Haematology*. 106, 47-54

Kerrigan J, Humphrey K, Duscheiko G, Foster G, Rosenberg W (1999) A novel approach to markov modelling: a computer forecasting tool to model the costs and consequences of the management of the hepatitis C virus (HCV). *International journal of technology assessment in health care*. 15, 499

Ilersich L, Howard P (1999) Pharmacoeconomic analysis of clodronate and pamidronate in osteolytic bone disease in Canada and the UK. *Canadian Health Technology Assessment*

1998

Howard P, Hieke K, Kerrigan M, Smarrt P, McIntyre A, et al. (1998) Cost minimisation analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-hodgkin's lymphoma in the UK. *Satellite symposium of British Society of Haematology*

Sweetenham J, McIntyre A, Howard P, Smarrt P, Kerrigan M, et al. (1998) Comparative economic analysis of the treatment of relapsed low-grade B-cell non hodgkin's lymphoma (NHL) using CHOP, fludarabine or rituximab. *American Society of Hematology annual meeting*

HERON is a leading provider of health outcomes, pricing and reimbursement and data-analytics services to the healthcare industry.

To find out more, please visit our ISPOR booth (#67-68) or go to the website:

www.heronhealth.com

3322 US Highway 22 West,
Suite 204
Branchburg
NJ 08876

United States

Email:
enquiries@herongroup.co.uk

Tel: +1 908 450 9922
Fax: +1 908 864 0137

Spirella Building
Bridge Road
Letchworth Garden City
Hertfordshire
SG6 4ET

United Kingdom

Email:
enquiries@herongroup.co.uk

Tel : +44 1462 476543
Fax: +44 1462 476544

Bldg. C 3 Floor
Plot No. 22 - 23
Rajiv Gandhi IT Park
Vill. Kishangarh
Chandigarh - 160 101

India